Management Strategies for Refractory Status Epilepticus

Refractory status epilepticus (RSE) is defined by seizure activity that persists despite administration of first-line benzodiazepines and a subsequent second-line anti-seizure medicine. Management centres on rapid control of ongoing neuronal excitation to minimise secondary brain injury, systemic complications and mortality. A stepwise approach typically progresses from bolus intravenous diazepam or lorazepam to agents such as phenytoin, valproic acid or levetiracetam. When these fail, continuous infusions of anaesthetic drugs (midazolam, propofol, pentobarbital or thiopental) are initiated to achieve electroencephalographic burst suppression, thereby halting pathological synchronisation. Super-refractory cases—those unresponsive more than 24 hours after commencement of coma-inducing anaesthetics—may require novel strategies, including immunotherapy for suspected autoimmune or inflammatory aetiologies, neuromodulation such as vagus-nerve stimulation, ketogenic diet, inhaled anaesthetics (isoflurane) or surgical intervention. Continuous electroencephalography monitoring guides treatment intensity and helps prevent both breakthrough and withdrawal seizures. Despite a growing armamentarium of pharmacological and non-pharmacological options, outcome remains guarded, underlining the need for timely escalation, individualised dosing protocols and exploration of emerging therapies.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Management Strategies for Refractory Status Epilepticus publication trend

The graph below shows the total number of articles in management strategies for refractory status epilepticus across all publications each year (not limited to Nature Index journals).

Technical terms

Refractory status epilepticus: Seizure activity unresponsive to both first-line benzodiazepines and a second-line anti-seizure medicine.

Super-refractory status epilepticus: Status epilepticus persisting or recurring more than 24 hours after the initiation of continuous anaesthetic infusion.

Continuous intravenous anaesthetic drugs: Sedative medications (such as midazolam, propofol, pentobarbital) administered by infusion to induce coma and suppress seizures.

Burst suppression: Electroencephalographic pattern of alternating high-voltage bursts and suppressed activity targeted during continuous anaesthetic therapy to control seizures.

Anti-seizure medicine (ASM): Pharmacological agent, including phenytoin, levetiracetam or valproic acid, used to terminate or prevent seizure activity.

Electroencephalography (EEG): Neurophysiological monitoring technique that records electrical brain activity to guide treatment intensity and assess seizure control.

References

1. Valproic acid as adjuvant treatment for convulsive status epilepticus: a randomised clinical trial. Critical Care (2023).
2. Efficacy of Perampanel in Refractory and Super-Refractory Status Epilepticus with Suspected Inflammatory Etiology: A Case Series. Pharmaceuticals (2023).
3. Systematic review and meta-analysis of propofol versus barbiturates for controlling refractory status epilepticus. BMC Neurology (2019).